A Multiple Myeloma Roundtable: Treatment Trends and Recent Clinical Advances
Figure 1 from Patterns of improved survival in patients with multiple myeloma in the twenty-first century: a population-based study. | Semantic Scholar
Progression-free and overall survival for high-risk patients with relapsed or refractory multiple myeloma (RRMM) who received carfilzomib-based regimens
Young age and autologous stem cell transplantation are associated with improved survival in newly diagnosed multiple myeloma - ScienceDirect
Outcome and survival of myeloma patients diagnosed 2008–2015. Real-world data on 4904 patients from the Swedish Myeloma Registry | Haematologica
Age-dependent overall survival of 2,907 newly diagnosed Danish patients... | Download Scientific Diagram
Impact of Novel Therapies on Multiple Myeloma Survival– Current and Future Outcomes - Clinical Lymphoma, Myeloma and Leukemia
Overall survival with daratumumab, bortezomib, melphalan, and prednisone in newly diagnosed multiple myeloma (ALCYONE): a randomised, open-label, phase 3 trial - The Lancet
Kaplan-Meier curves for overall survival for patients with genetic... | Download Scientific Diagram
Overall survival of multiple myeloma based on clinical stage at... | Download Scientific Diagram
Poor outcomes of immunoglobulin D multiple myeloma patients in the era of novel agents: a single-center experience | Cancer Communications | Full Text
The Clinical Course of Multiple Myeloma in the Era of Novel Agents: A Retrospective, Single-Center, Real-World Study | Atlantis Press
Daratumumab, Lenalinomide, and Dexamethasone for Myeloma | NEJM Resident 360
Prognostic Nomogram for the Overall Survival of Patients with Newly Diagnosed Multiple Myeloma
Overall survival of transplant eligible patients with newly diagnosed multiple myeloma: comparative effectiveness analysis of modern induction regimens on outcome | Blood Cancer Journal
Expression of interleukin-32 in bone marrow of patients with myeloma and its prognostic significance
Frontiers | Staging System to Predict the Risk of Relapse in Multiple Myeloma Patients Undergoing Autologous Stem Cell Transplantation
Mortality from Multiple Myeloma Within One Year Following Autologous Stem Cell Transplantation: Defining an Ultra-high Risk Population - Clinical Lymphoma, Myeloma and Leukemia
Real-World Treatment Patterns, Outcomes, and Healthcare Resource Utilization in Relapsed or Refractory Multiple Myeloma: Evidence from a Medical Record Review in France
Trends in the multiple myeloma treatment landscape and survival: a U.S. analysis using 2011–2019 oncology clinic electronic he
Modern multiple myeloma therapy: deep, sustained treatment response and good clinical outcomes - Landgren - 2017 - Journal of Internal Medicine - Wiley Online Library
